Opendata, web and dolomites

NEW DEAL SIGNED

New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEW DEAL project word cloud

Explore the words cloud of the NEW DEAL project. It provides you a very rough idea of what is the project "NEW DEAL" about.

inhibition    transit    deal    thanks    stage    mucus    avenues    transfer    progress    cells    manner    membrane    drawbacks    barrier    translation    young    combining    capsules    gastroenterology    successful    mediated    manufacturing    inflammatory    clinics    experts    people    scientists    clinical    inhibit    tolerability    oral    biology    tract    diseases    smes    immunology    expertise    gut    plan    carriers    historic    selective    company    preclinical    therapies    immunogenicity    good    nanosafety    pharma    polymeric    nanomedicine    intestinal    antibodies    proven    patients    evaluation    locally    carefully    lipid    efficacy    nanostructured    administration    radical    medicinal    safety    bowel    mean    jak    protecting    industrial    jak3    nanotherapeutics    regulatory    transport    safer    therapy    validated    immune    solution    therapeutic    inflamed    ibd    disorders    innovative    background    plasma    gi    designed    rnai    submission    convenience    generate    sirna    brings   

Project "NEW DEAL" data sheet

The following table provides information about the project.

Coordinator
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES 

Organization address
address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015
website: www.cea.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.newdeal-project.eu
 Total cost 5˙999˙178 €
 EC max contribution 5˙999˙178 € (100%)
 Programme 1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-NMBP-2016-two-stage
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) coordinator 1˙915˙936.00
2    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 774˙723.00
3    NANOIMMUNOTECH SL ES (VIGO PONTEVEDRA) participant 506˙813.00
4    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 475˙258.00
5    PRODIGEST BE (GENT ZWIJNAARDE) participant 463˙343.00
6    LABORATOIRES MAYOLY SPINDLER FR (CHATOU) participant 448˙750.00
7    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) participant 384˙965.00
8    SEPS PHARMA BE (DIEPENBEEK) participant 373˙125.00
9    EUROPEAN RESEARCH SERVICES GMBH DE (MUENSTER) participant 233˙337.00
10    SCIENSEED SL ES (MADRID) participant 190˙288.00
11    ALAN BOYD CONSULTANTS LIMITED UK (CREWE) participant 188˙750.00
12    SPARKS & CO FR (PARIS) participant 43˙886.00

Map

 Project objective

Inflammatory bowel diseases (IBD) are the second most common immune-mediated disorders in Europe, affecting more particularly young people. The current therapies, including antibodies, show three main drawbacks: efficacy, tolerability and convenience. NEW DEAL solution will offer radical therapeutic progress for all IBD patients, thanks to the improved efficacy and increased safety of the specific JAK3 inhibition, which has been proven in clinics to be a target of great interest, the better tolerability of siRNA in term of immunogenicity and the good convenience with oral administration. To achieve this challenge, we will address three objectives: i) Specifically inhibit JAK 3 in a highly selective and safer manner by the mean of siRNA carefully designed and validated, ii) Deliver the siRNA therapeutic locally to the inflamed gut, by combining innovative nanostructured lipid carriers enabling their transport across the mucus, the intestinal barrier and the plasma membrane of the target cells, with polymeric capsules for protecting siRNA nanotherapeutics during their transit along the GI tract, thus allowing an oral administration, and iii) Promote the clinical translation and the future industrial transfer of this new clinical product, by addressing manufacturing, safety and efficacy evaluation at the late preclinical stage, to generate a Regulatory Submission Package and a Clinical Development Plan. The NEW DEAL project brings together clinical experts on IBD, leading scientists in nanomedicine, RNAi biology and immunology, innovative SMEs with a strong background in nanosafety, design of capsules and regulatory issues and an established pharma company with historic expertise on gastroenterology medicinal products. If successful, NEW DEAL will open new avenues for siRNA-based therapy in IBD with oral administration.

 Deliverables

List of deliverables.
Basic communication tools Websites, patent fillings, videos etc. 2019-05-14 12:33:11

Take a look to the deliverables list in detail:  detailed list of NEW DEAL deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Benedikt C. Huck, Olga Hartwig, Alexander Biehl, Konrad Schwarzkopf, Christian Wagner, Brigitta Loretz, Xabier Murgia, Claus-Michael Lehr
Macro- and Microrheological Properties of Mucus Surrogates in Comparison to Native Intestinal and Pulmonary Mucus
published pages: 3504-3512, ISSN: 1525-7797, DOI: 10.1021/acs.biomac.9b00780
Biomacromolecules 20/9 2020-03-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEW DEAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEW DEAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.2.)

nTRACK (2017)

Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

Read More  

iNanoBIT (2017)

Integration of Nano- and Biotechnology for beta-cell and islet Transplantation

Read More  

NOBEL (2017)

Mobilising the European nano-biomedical ecosystem

Read More